Somewhere in Satna, in Madhya Pradesh, a child received a blood transfusion and later tested positive for HIV. The same happened in West Singhbhum in Jharkhand, in Jaipur, in Kamrup. Different states, different hospitals, the same systemic failure: a screening protocol existed on paper, and was absent at the needle. These were not freak accidents. They were the predictable output of a regulatory architecture that confused recommendation with requirement.
The Centre has now decided to change that architecture. According to documents reviewed by Mint and two officials aware of the matter, the government is making external quality audits and centralized digital inventory tracking legally mandatory for all of India's 4,153 blood banks — converting what were voluntary guidelines into binding requirements under the Drugs Rules. The move aligns India's transfusion safety protocols with WHO, European Union, and US accreditation standards.
From Advisory to Enforceable
The distinction between a guideline and a law is not merely bureaucratic. In practice, it means a blood bank that participates in quality monitoring because it chooses to versus one that participates because failure carries legal consequence. India's current framework offers the former. Facilities could, and many did, ignore External Quality Assessment Schemes — known as EQAS — without penalty.
The official document cited by Mint states plainly: "Participation in External Quality Assessment Schemes ensures continuous quality monitoring and standardization across blood centres. At present, EQAS participation is recommended but lacks explicit enforceability under statutory provisions." That sentence identifies the fault line. Every transfusion-transmitted infection that has emerged from a facility with nominal compliance but no external verification traces back to that gap between recommended and required.
The government's response is direct. Embed EQAS participation in the Drugs Rules. Require registration on e-RaktKosh — the central digital platform managed by the Ministry of Health and Family Welfare and C-DAC — to enable real-time monitoring of blood stocks. Mandate inspections at state level, then anchor those inspections in statute. Once incorporated under the Drugs Rules, as one official told Mint, "it will become a legal requirement."
The Geography of Failure
The cases that triggered this overhaul share a geography that matters. Satna, West Singhbhum, Kamrup — these are not tier-one cities with internationally accredited hospitals and well-resourced state drug controllers. They are places where the gap between central regulation and local implementation has historically been widest. The professional donor racket — where paid donors, often from high-risk populations, supply blood that feeds facilities unable to secure voluntary donations — has persisted precisely in these markets. The reform's explicit aim to "dismantle the culture of replacement donations" and move toward a fully voluntary, non-remunerated blood donation system addresses the supply-side of the problem. The audit mandate addresses the process side.
Together, they close a circle. But the circle only closes if the enforcement arm — state drug controllers — has the capacity to act. India has 4,153 blood banks and a central drug regulator, CDSCO, whose inspection bandwidth cannot plausibly cover that many facilities on any reasonable cycle. The entire architecture of this reform depends on states conducting audits at their own level, as the official quoted by Mint confirmed is already happening — but it was not previously mandatory. Making it mandatory is necessary. Making it effective requires resourcing the state-level inspection apparatus that most observers agree is currently uneven across the country.
The e-RaktKosh Bet
A second reform runs parallel to the audit mandate, quieter but potentially more consequential at scale: the mandatory registration of all blood banks on e-RaktKosh for real-time inventory tracking. This is where India's digital health infrastructure matters most in the blood safety story.
The platform already exists and operates. The problem has been adoption. Voluntary registration produces partial data, and partial data produces blind spots in national stock management. A district-level shortage in one state goes invisible to administrators in another. Hoarding by better-resourced facilities cannot be detected from the centre. The mandate converts a useful platform into a functioning surveillance system.
Analysts working on India's health technology policy have long argued that the country's digital health stack — e-RaktKosh included — represents a genuine institutional advantage that remains under-leveraged because the enforcement mandate has been absent. This reform provides that mandate. The question is whether the data flowing into the platform will be acted upon in real time or whether it becomes another repository of information that sits unused between crises.
A Reform With a Second Audience
India's annual blood requirement is 14.6 million units. That number alone frames the stakes in domestic public health terms. But the reform carries a second audience beyond Indian patients: the international bodies whose accreditation decisions shape the competitiveness of Indian hospitals seeking foreign patients.
Joint Commission International accreditation — the benchmark for hospitals seeking to attract medical tourists — requires demonstrably safe blood supply chains. WHO prequalification pathways, relevant for Indian hospitals operating in global health programmes, carry similar expectations. A blood banking system where EQAS participation rates remain below sixty percent in several states, as public health researchers familiar with NACO data have noted, does not strengthen these credentials. A system where EQAS participation is legally mandatory and digitally tracked does.
This is the reform's strategic dimension, and it should be stated without embarrassment: improving blood safety standards is the right thing to do for Indian patients, and it also strengthens India's case for international healthcare recognition. These are not competing goals. The same regulatory upgrade that protects a child in Kamrup also signals to a hospital administrator in Singapore that an Indian facility meets global benchmarks. Converting a domestic health reform into a diplomatic and trade asset is not cynicism — it is competent statecraft applied to health policy.
The Structural Fault Line
Health in India is a concurrent subject. The Centre sets the rules; states license, inspect, and enforce. This constitutional reality is the structural fault line running beneath every central health mandate. The blood bank reform is no exception. Amending the Drugs Rules in Delhi is tractable. Ensuring that a state drug controller in a fiscally stretched state actually conducts and acts on EQAS audit findings is the harder problem.
Public health experts have previously flagged that voluntary quality frameworks without legal teeth create a two-tier system: private blood banks in metropolitan centres comply, while rural facilities lag. The legal mandate removes the voluntary character of compliance. It does not, by itself, remove the resourcing gap between a well-staffed state drug control office and one operating with a fraction of the personnel needed to inspect hundreds of facilities annually. The Parliamentary Standing Committee on Health and Family Welfare has in prior sessions identified CDSCO's limited inspection capacity as the primary bottleneck to blood bank compliance. That concern applies with equal force to state-level enforcement arms.
The reform will succeed or stall at that implementation junction. A time-bound capacity-building programme for state drug controllers — the actual enforcement arm of this mandate — is not an optional supplement to the legislative change. It is the difference between a law and an outcome.
The architecture of the reform is sound and overdue. The e-RaktKosh mandate leverages infrastructure that already exists. The EQAS requirement aligns India with standards its peer health systems already meet. The ambition to end the professional donor racket addresses a market failure that has persisted for decades. The test now is whether the Centre pairs the legislative announcement with the unglamorous work of building state enforcement capacity — because a blood safety mandate that exists in the Drugs Rules but not in district-level practice offers a child in Satna exactly the same protection as the advisory it replaced.
